I'm joined today by Faisal Zain, a leading expert in U.S. healthcare policy with deep insights into hospital finance and pharmaceutical pricing. We're here to unpack the recent, and for many, welcome decision by the Department of Health and Human Services to scrap its controversial 340B
The long-standing challenge for health insurers has always been peering through the fog of information asymmetry, where a potential policyholder knows far more about their personal health risks than the underwriter ever could. This fundamental imbalance has traditionally led to generalized risk
For decades, the intricate and often bewildering system of prescription drug pricing in the United States has been orchestrated by powerful but little-understood intermediaries whose operations remained largely shielded from public and regulatory view. These entities, known as Pharmacy Benefit
In a powerful demonstration of resurgent investor confidence within the biotechnology sector, Eikon Therapeutics has successfully launched its Initial Public Offering, securing an impressive $381 million to fuel the advancement of its promising pipeline of cancer drug candidates. This event not
The persistent administrative drag on clinical practice has created a system where highly trained medical professionals spend nearly as much time with keyboards as they do with patients. This has become a central paradox of modern medicine, undermining both clinician well-being and the financial
In a legislative maneuver that fused political necessity with policy ambition, a government funding bill designed to avert a shutdown has become the unlikely vessel for some of the most consequential healthcare reforms of the decade. While Washington focused on the drama of appropriations, the bill
